CIK 0001854270 · <br>Emerging growth company
Senti Biosciences Holdings, Inc.
Sign in to watch- Ticker
- SNTI
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 862437900
- Phone
- (650) 239-2030
- Business address
- 2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO, CA, 94080
- Former names
- Senti Biosciences, Inc., Senti Biosciences, Inc.\, Dynamics Special Purpose Corp.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-10 | Rajangam Kanya Pres. & Chief Med. & Dev. Off. | Conversion · Series A Convertible Preferred Stock | −33 | $2,250.00 | $74K | 0 |
| 2025-03-07 | Schulz Fran Director | Grant or award · Stock Option (Right to Buy) | +43,900 | 43,900 | ||
| 2025-03-07 | Collins James J. Director | Grant or award · Stock Option (Right to Buy) | +43,900 | 43,900 | ||
| 2025-03-07 | Tang Donald F Director | Grant or award · Stock Option (Right to Buy) | +43,900 | 43,900 | ||
| 2025-03-07 | COOPERSTONE BRENDA Director | Grant or award · Stock Option (Right to Buy) | +43,900 | 43,900 | ||
| 2025-03-07 | Hsiung Feng Director | Grant or award · Stock Option (Right to Buy) | +43,900 | 43,900 | ||
| 2025-03-07 | Cross John Harry III Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +174,200 | 174,200 | ||
| 2025-03-07 | Mathers Edward T Director | Grant or award · Stock Option (Right to Buy) | +43,900 | 43,900 | ||
| 2025-03-07 | Rajangam Kanya Pres. & Chief Med. & Dev. Off. | Grant or award | +78,363 | 86,984 | ||
| 2025-03-07 | Lu Timothy K CEO and Interim PFO and PAO | Grant or award | +642,358 | 724,440 | ||
| 2025-03-06 | Rajangam Kanya Pres. & Chief Med. & Dev. Off. | Grant or award · Stock Option (Right to Buy) | +235,088 | 235,088 | ||
| 2025-03-06 | Lu Timothy K CEO and Interim PFO and PAO | Grant or award · Stock Option (Right to Buy) | +1,927,073 | 1,927,073 | ||
| 2025-02-06 | Lu Timothy K CEO | Sale | −545 | $4.36 | $2K | 82,082 |
| 2025-02-06 | Rajangam Kanya Pres. & Chief Med. & Dev. Off. | Sale | −182 | $4.37 | $795 | 8,621 |
| 2025-02-04 | Lu Timothy K CEO | Sale | −3,922 | $4.07 | $16K | 82,627 |
| 2025-02-04 | Rajangam Kanya Pres. & Chief Med. & Dev. Off. | Sale | −1,297 | $4.07 | $5K | 8,803 |
| 2024-12-09 | BAYER HEALTHCARE LLC 10% owner | Purchase · Series A Convertible Preferred Stock | +2,222 | 2,222 | ||
| 2024-12-09 | BAYER HEALTHCARE LLC 10% owner | Purchase · Warrant | +3,333,000 | 3,330,000 | ||
| 2024-12-09 | Tang Donald F Director | Grant or award · Stock Option (Right to Buy) | +12,500 | 12,500 | ||
| 2024-12-09 | Schulz Fran Director | Grant or award · Stock Option (Right to Buy) | +12,500 | 12,500 |
Page 2 of 4 · 79 trades